Moreover, PRDX1 may play an important role in modulating EGFR-TKI therapeutic sensitivity and tumor immunity, highlighting its promise as a therapeutic target to improve clinical outcomes in LUAD. The gene discussed is EGFR; the disease is neoplasm.